<DOC>
	<DOCNO>NCT01345682</DOCNO>
	<brief_summary>This randomise , open-label , phase III study perform patient R/M head neck squamous cell carcinoma ( HNSCC ) progress platinum-based therapy . The objective trial compare efficacy safety afatinib versus methotrexate</brief_summary>
	<brief_title>LUX-Head &amp; Neck 1 : A Phase III Trial Afatinib ( BIBW2992 ) Versus Methotrexate Treatment Recurrent and/or Metastatic ( R/M ) Head Neck Squamous Cell Cancer After Platinum Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically confirm R/M HNSCC oral cavity , oropharynx , hypopharynx larynx , amenable salvage surgery radiotherapy 2 . Documented progressive disease base investigator assessment accord Response Evaluation Criteria Solid Tumours ( RECIST ) follow receipt least two cycle cisplatin carboplatin administer R/M disease 3 . Measurable disease accord RECIST 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Exclusion criterion : 1 . Progressive disease within three month completion curatively intend treatment locoregionally advance metastatic HNSCC 2 . Any one previous platinum base systemic regimen give R/M disease 3 . Prior treatment epidermal growth factor receptor ( EGFR ) target small molecule 4 . Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>